H-group (homology)
1075.1 Type II ABC exporter transmembrane domain-related
Ligands and drugs
2,793
Member domains
211
with ligand contacts (≤ 4 Å)
7.6% of members
99
with DrugDomain annotations
3.5% of members
77
with a DrugBank compound
2.8% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 1075.1 belongs to X-group 1075 Type II ABC exporter transmembrane domain fold, which binds 8.7 ligand superclasses per 20 proteins, broader than 72% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB04540 | CLR | Cholesterol | 34 |
| DB00141 | NAG | N-Acetylglucosamine | 8 |
| DB00171 | ATP | ATP | 8 |
| DB01030 | TTC | Topotecan | 6 |
| DB06240 | R1H | Tariquidar | 6 |
| DB04327 | PEE | Phosphatidylethanolamine | 5 |
| DB01204 | MIX | Mitoxantrone | 4 |
| DB02777 | PLC | Diundecyl Phosphatidyl Choline | 4 |
| DB03796 | PLM | Palmitic Acid | 4 |
| DB07640 | DCQ | 2-decyl-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione | 4 |
| DB16829 | A8S | Abscisic Acid | 4 |
| DB16833 | ADP | Adenosine disphosphate | 4 |
| DB00619 | STI | Imatinib | 2 |
| DB01016 | — | Glyburide | 2 |
| DB01599 | — | — | 2 |
| DB03472 | MA4 | Cyclohexyl-Hexyl-Beta-D-Maltoside | 2 |
| DB04038 | ERG | Ergosterol | 2 |
| DB05482 | RS4 | SN-38 | 2 |
| DB04851 | — | — | 1 |
| DB08357 | P4G | Diethylene glycol diethyl ether | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CLR | CHOLESTEROL | 48 |
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 31 |
| JSG | (2~{R},4~{R},5~{R},6~{R})-6-[(1~{R})-1,2-bis(oxidanyl)ethyl]-2-[(2~{R},4~{R},5~{R},6~{R})-6-[(1~{R})-1,2-bis(oxidanyl)ethyl]-5-[(2~{S},3~{S},4~{R},5~{R},6~{R})-6-[(1~{S})-1,2-bis(oxidanyl)ethyl]-4-[(2~{R},3~{S},4~{R},5~{S},6~{R})-6-[(1~{S})-2-[(2~{S},3~{S},4~{S},5~{S},6~{R})-6-[(1~{S})-1,2-bis(oxidanyl)ethyl]-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-1-oxidanyl-ethyl]-3,4-bis(oxidanyl)-5-phosphonooxy-oxan-2-yl]oxy-3-oxidanyl-5-phosphonooxy-oxan-2-yl]oxy-2-carboxy-2-[[(2~{R},3~{S},4~{R},5~{R},6~{R})-5-[[(3~{R})-3-dodecanoyloxytetradecanoyl]amino]-6-[[(2~{R},3~{S},4~{R},5~{R},6~{R})-3-oxidanyl-5-[[(3~{R})-3-oxidanyltetradecanoyl]amino]-4-[(3~{R})-3-oxidanyltetradecanoyl]oxy-6-phosphonooxy-oxan-2-yl]methoxy]-3-phosphonooxy-4-[(3~{R})-3-tetradecanoyloxytetradecanoyl]oxy-oxan-2-yl]methoxy]oxan-4-yl]oxy-4,5-bis(oxidanyl)oxane-2-carboxylic acid | 14 |
| 3PE | 1,2-Distearoyl-sn-glycerophosphoethanolamine | 13 |
| PLM | PALMITIC ACID | 11 |
| Z41 | (2S)-3-hydroxypropane-1,2-diyl dihexadecanoate | 11 |
| ADP | ADENOSINE-5'-DIPHOSPHATE | 9 |
| A8S | (2Z,4E)-5-[(1S)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]-3-methylpenta-2,4-dienoic acid | 8 |
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 8 |
| BWQ | ~{tert}-butyl 3-[(2~{S},5~{S},8~{S})-14-cyclopentyloxy-2-(2-methylpropyl)-4,7-bis(oxidanylidene)-3,6,17-triazatetracyclo[8.7.0.0^{3,8}.0^{11,16}]heptadeca-1(10),11,13,15-tetraen-5-yl]propanoate | 8 |
| MNR | PROTOPORPHYRIN IX CONTAINING MN | 8 |
| R1H | tariquidar | 6 |
| TTC | (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE | 6 |
| Y01 | CHOLESTEROL HEMISUCCINATE | 6 |
| ANP | PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER | 5 |
| PEE | 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine | 5 |
| POV | (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate | 5 |
| AOV | ADP ORTHOVANADATE | 4 |
| DCQ | 2-decyl-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione | 4 |
| FY5 | estrone 3-sulfate | 4 |